Frankfurt - Delayed Quote EUR

Linc AB (6ZB.F)

Compare
8.25 -0.27 (-3.17%)
At close: June 14 at 8:04 AM GMT+2
Loading Chart for 6ZB.F
DELL
  • Previous Close 8.52
  • Open 8.25
  • Bid --
  • Ask --
  • Day's Range 8.25 - 8.25
  • 52 Week Range 4.47 - 8.52
  • Volume 229
  • Avg. Volume 7
  • Market Cap (intraday) 477.761M
  • Beta (5Y Monthly) 1.00
  • PE Ratio (TTM) 13.31
  • EPS (TTM) 0.62
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Linc AB is a private equity and venture capital firm, specializing in early and mature stage investments in pharmaceutical, life-science and med-tech companies. It prefers to invest in drug development usually take place at an early stage, while investments in medical technology are made in more mature businesses. The investments are made in both private and public companies and in research and operational companies. The firm prefers to invest in Nordic companies. It usually invests from SEK 25 million ($2.99 million) and SEK 250 million ($29.99 million), the first investment often being a relatively small one and the follow-up investments comprising the larger part of the investment. Linc AB was founded in 1991 and based in Stockholm, Sweden.

linc.se

2

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 6ZB.F

Performance Overview: 6ZB.F

Trailing total returns as of 6/14/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

6ZB.F
43.48%
OMX Stockholm 30 Index
6.81%

1-Year Return

6ZB.F
48.38%
OMX Stockholm 30 Index
10.37%

3-Year Return

6ZB.F
12.79%
OMX Stockholm 30 Index
12.42%

5-Year Return

6ZB.F
18.72%
OMX Stockholm 30 Index
13.12%

Compare To: 6ZB.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 6ZB.F

Valuation Measures

Annual
As of 6/14/2024
  • Market Cap

    477.22M

  • Enterprise Value

    432.76M

  • Trailing P/E

    13.27

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.47k

  • Price/Book (mrq)

    1.50

  • Enterprise Value/Revenue

    1.34k

  • Enterprise Value/EBITDA

    12.41

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    104.31%

  • Return on Assets (ttm)

    6.87%

  • Return on Equity (ttm)

    11.83%

  • Revenue (ttm)

    384.44M

  • Net Income Avi to Common (ttm)

    401.01M

  • Diluted EPS (ttm)

    0.62

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    500.62M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    216.61M

Research Analysis: 6ZB.F

Company Insights: 6ZB.F

Research Reports: 6ZB.F